Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00112528 | Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 53 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 13, 2016 | clinicaltrials |
| NCT00059826 | Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer | completed | Phase 2 | 89 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 7, 2016 |
| NCT02984501 | Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer | completed | Phase 2 | 41 | Campus Bio-Medico UniversityOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02726854 | Apatinib as Second-line Treatment of Advanced Pancreatic Cancer(Apslpanc) | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01369420 | NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 10 | Angiodynamics, Inc.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT02565641 | A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 63 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00499486 | Sirolimus in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT01661114 | A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers | completed | Phase 2 | 39 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT00260364 | Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer(TARGET) | completed | Phase 1 / Phase 2 | 44 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01050426 | A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)(PERU) | terminated | Phase 2 | 17 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01045941 | Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2016 | clinicaltrials |
| NCT00726037 | A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer | terminated | Phase 2 | 7 | Loyola UniversityOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT02329717 | Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma | unknown | Phase 2 | 50 | Phoenix Biotechnology, IncINDUSTRY | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01188109 | Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision | terminated | Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 28, 2016 | clinicaltrials |
| NCT00336700 | A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer | terminated | Phase 2 | 25 | Herbert J. Zeh, III MD, FACSOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01488552 | Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 60 | Pancreatic Cancer Research TeamOTHER | 1 | Aug 18, 2016 | clinicaltrials |
| NCT02863367 | A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer(OECTAPGAMPC) | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01304160 | Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 10 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 5, 2016 | clinicaltrials |
| NCT00689715 | Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas(EUS-EP) | unknown | Phase 2 / Phase 3 | 50 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT00958841 | Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | terminated | Phase 2 | 118 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 26, 2016 | clinicaltrials |
| NCT00882310 | A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer | completed | Phase 2 | 37 | Columbia UniversityOTHER | 0 | Jul 25, 2016 | clinicaltrials |
| NCT00996333 | Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB) | completed | Phase 2 | 46 | Columbia UniversityOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT02270554 | A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy | completed | Phase 2 | 120 | Wakayama Medical UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT00003546 | Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer | completed | Phase 2 | 43 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT00026130 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer | completed | Phase 2 | 81 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT01888965 | Maintenance Dovitinib for Colorectal and Pancreas Cancer | terminated | Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT00004190 | Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 59 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00012220 | Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas | completed | Phase 2 | 259 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00026403 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 48 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00006467 | Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas | completed | Phase 2 | 48 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT02382263 | Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer(FRAGANCE) | completed | Phase 1 / Phase 2 | 224 | PH Research, S.L.OTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00696696 | Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer | completed | Phase 2 | 45 | NYU Langone HealthOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT01473303 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jun 28, 2016 | clinicaltrials |
| NCT00869258 | Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar | completed | Phase 2 | 32 | Columbia UniversityOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT00674973 | A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 207 | Hoffmann-La RocheINDUSTRY | 19 | Jun 17, 2016 | clinicaltrials |
| NCT00871169 | Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 61 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT00416767 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Federation Francophone de Cancerologie DigestiveOTHER | 0 | May 30, 2016 | clinicaltrials |
| NCT01416662 | Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | completed | Phase 2 | 120 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | May 30, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT00766636 | Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | May 19, 2016 | clinicaltrials |
| NCT02468076 | Radiofrequency Ablation for Biliopancreatic Malignancy(IGNITE-1) | completed | Phase 2 | 18 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | May 2, 2016 | clinicaltrials |
| NCT02754180 | Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes | unknown | Phase 2 | 110 | Peking Union Medical College HospitalOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) | completed | Phase 2 | 202 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 15 | Apr 8, 2016 | clinicaltrials |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 7, 2016 | clinicaltrials |
| NCT00383149 | A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer | completed | Phase 2 | 58 | R-PharmINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01658943 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy(S1115) | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Dec 13, 2016source: clinicaltrials